Literature DB >> 17072333

Cross-talk between nuclear receptors and nuclear factor kappaB.

K De Bosscher1, W Vanden Berghe, G Haegeman.   

Abstract

A variety of studies have shown that some activated nuclear receptors (NRs), especially the glucorticoid receptor, the estrogen receptor and peroxisome proliferator-activated receptor, can inhibit the activity of the transcription factor nuclear factor kappaB (NF-kappaB), which plays a key role in the control of genes involved in inflammation, cell proliferation and apoptosis. This review describes the molecular mechanisms of cross-talk between NRs and NF-kappaB and the biological relevance of this cross-talk. The importance and mechanistic aspects of selective NR modulation are discussed. Also included are future research prospects, which will lead to a new era in the field of NR research with the aim of specifically inhibiting NF-kappaB-driven gene expression for anti-inflammatory, anti-tumor and immune-modulatory purposes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072333     DOI: 10.1038/sj.onc.1209935

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  98 in total

Review 1.  Effects of social isolation on glucocorticoid regulation in social mammals.

Authors:  Louise C Hawkley; Steve W Cole; John P Capitanio; Greg J Norman; John T Cacioppo
Journal:  Horm Behav       Date:  2012-06-01       Impact factor: 3.587

2.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

Review 3.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

4.  Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.

Authors:  Chunyu Wang; Julie Ann Mayer; Abhijit Mazumdar; Kirsten Fertuck; Heetae Kim; Myles Brown; Powel H Brown
Journal:  Mol Endocrinol       Date:  2011-08-11

5.  Effect of estrogen-active compounds on the expression of RACK1 and immunological implications.

Authors:  Erica Buoso; Mirco Masi; Valentina Galbiati; Ambra Maddalon; Martina Iulini; Maša Kenda; Marija Sollner Dolenc; Marina Marinovich; Marco Racchi; Emanuela Corsini
Journal:  Arch Toxicol       Date:  2020-04-23       Impact factor: 5.153

6.  PPARγ and NF-κB regulate the gene promoter activity of their shared repressor, TNIP1.

Authors:  Igor Gurevich; Carmen Zhang; Priscilla C Encarnacao; Charles P Struzynski; Sarah E Livings; Brian J Aneskievich
Journal:  Biochim Biophys Acta       Date:  2011-10-07

7.  18β-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARγ and Nrf2 upregulation.

Authors:  Ayman M Mahmoud; Hussein S Al Dera
Journal:  Genes Nutr       Date:  2015-09-19       Impact factor: 5.523

8.  Phosphorylation of Farnesoid X Receptor at Serine 154 Links Ligand Activation With Degradation.

Authors:  Takuyu Hashiguchi; Shingo Arakawa; Shogo Takahashi; Frank J Gonzalez; Tatsuya Sueyoshi; Masahiko Negishi
Journal:  Mol Endocrinol       Date:  2016-08-29

9.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

10.  Vinclozolin exposure in utero induces postpubertal prostatitis and reduces sperm production via a reversible hormone-regulated mechanism.

Authors:  Prue A Cowin; Elspeth Gold; Jasna Aleksova; Moira K O'Bryan; Paul M D Foster; Hamish S Scott; Gail P Risbridger
Journal:  Endocrinology       Date:  2010-01-07       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.